Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 79 clinical trials
A Study Of TAK-981 Given With Monoclonal Antibodies In Adults With Relapsed or Refractory Multiple Myeloma

TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies to treat participants who have relapsed or refractory multiple myeloma. The main aims of the study are to

  • 0 views
  • 22 Sep, 2021
  • 15 locations
Selinexor Pomalidomide and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma The SCOPE Trial

treating patients with multiple myeloma that has come back (relapsed) and does not respond to treatment with proteasome inhibitors and immunomodulatory drugs (refractory). Selinexor is an oral agent that

  • 0 views
  • 21 May, 2021
  • 1 location
Study of the Safety Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

of the second generation oral XPO1 inhibitor KPT-8602 in participants with relapsed/refractory multiple myeloma (MM), metastatic colorectal cancer (mCRC), metastatic castration resistant prostate

dexamethasone
refractory multiple myeloma
  • 0 views
  • 24 Sep, 2021
  • 10 locations
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex

This is a Phase 1/2, multi-centre, single-arm, open-label, dose-escalation study that will evaluate the safety and efficacy of IV GSK2857916 in combination with PO pomalidomide and low-dose PO dexamethasone in subjects with relapsed and/or refractory MM.

  • 69 views
  • 25 Jan, 2021
  • 10 locations
Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.

Allogeneic hematopoietic stem cell transplantation (HTC) is the only curative option for many patients with hematologic malignancies but >50% of this patients will develop extensive chronic graft-versus-host disease (cGVHD), which remains the most important complication after HTC. Classically, the most effective strategies to prevent GVHD have not improved survival; therefore, …

cyclophosphamide
neutrophil count
graft versus host disease
platelet count
cell transplantation
  • 2 views
  • 27 Jan, 2021
  • 11 locations
Trial With LAVA-051 in Patients With Relapsed/Refractory CD1d (Cluster of Differentiation (CD)1d)-Positive CLL MM AML

), Multiple Myeloma (MM) or Acute Myeloid Leukemia (AML). Condition or disease: Chronic Lymphocytic Leukemia (CLL); Multiple Myeloma (MM); Acute Myeloid Leukemia (AML) Intervention/ treatment

chronic lymphocytic leukemia
multiple myeloma
platelet count
leukemia
  • 0 views
  • 28 Jun, 2021
  • 3 locations
Study to Evaluate CCS1477 in Haematological Malignancies

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk

multiple myeloma
lymphoma
hodgkin's disease
cancer
myeloid leukemia
  • 19 views
  • 13 Aug, 2021
  • 4 locations
CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

This is an open, single-arm, phase I/phase II clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of hematopoietic and lymphoid malignancies. A total of 50 patients are planned to be enrolled over a period of 2 years.

cancer
  • 148 views
  • 22 Jan, 2021
  • 1 location
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Background In allogeneic stem cell transplantation (SCT), stem cells are taken from a donor and given to a recipient. Sometimes the recipient s immune system destroys the donor s cells. Or donor immune cells attack the recipient s tissues, called graft-versus-host disease (GVHD). This is less likely when the recipient …

minimal residual disease
immunofixation
remission
lymphoma
therapeutic agents
  • 23 views
  • 20 Sep, 2021
  • 2 locations
Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

groups for relapsed/refractory chronic lymphocytic leukaemia (CLL), AML/ myelodysplastic syndromes (MDS), and multiple myeloma (MM). Closed November 2020 Part 3 is a sequential, dose-escalation study of

immunotherapeutic agent
lymphoma
lymphocytic leukemia
hematologic malignancy
venetoclax
  • 111 views
  • 17 Sep, 2021
  • 13 locations